EPAS1 and clear cell renal carcinoma: To date, a phase III study of the HIF-2α inhibitor MK-6482 is underway on advanced clear cell renal cell carcinoma (NCT04195750), suggesting that targeting HIF-2α could be a promising strategy in a clinical setting.